Latest News and Press Releases

Molecure's Phase II KITE trial for OATD-01 in pulmonary sarcoidosis will continue without protocol changes following a positive IDMC review.

Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 30, 2026 – Update to Press...

Trésorerie et équivalents de trésorerie de 166,1 millions d'euros et 67,8 millions d'euros de dépôts à court terme2 au 30 juin 2026 Daix (France), New York City (New York, États-Unis), le 30...

Second-quarter 2026 Rezdiffra® (resmetirom) net sales of $364.3 million, representing year-over-year growth of 71% As of June 30, 2026, more than 49,000 patients on Rezdiffra, more than doubling from...

Cash and cash equivalents at €166.1 million and €67.8 million in short-term deposits2 as at June 30, 2026 Daix (France), New York City (New York, United States), July 29, 2026 – Inventiva (Euronext...

Trésorerie et équivalents de trésorerie de 166,1 millions d'euros et 67,8 millions d'euros de dépôts à court terme2 au 30 juin 2026 Daix (France), New York City (New York, États-Unis), le 29...

CONSHOHOCKEN, Pa., July 16, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) announced today that it will release its second-quarter 2026 financial results on Thursday, July...

Received two new U.S. Rezdiffra® (resmetirom) patents in F2/F3; both patents will be listed in the FDA’s Orange Book Received new U.S. resmetirom patent directed to a method of administering...

Exton, PA, July 08, 2026 (GLOBE NEWSWIRE) -- The European market for metabolic dysfunction-associated steatohepatitis (MASH) is entering a pivotal phase of development as increasing disease...

Tekton Research, a multi-specialty clinical research site organization, is expanding its partnership with Summit Clinical Research Solutions (“Summit”).